Claims
- 1. A transgenic mouse all of whose germ cells and somatic cells contain one or more recombinant constructs of an oncogene or a functionally inactivated tumor suppressor gene, each of said oncogene or functionally inactivated tumor suppressor gene being operably linked to a uroplakin promoter and said one or more recombinant constructs having been introduced into said mouse, or an ancestor of said mouse, at an embryonic stage, wherein said mouse exhibits the phenotype for progression or development of tumors in the bladder and wherein said transgene is expressed in the urothelium at a level sufficient to result in tumor growth in the bladder.
- 2. The transgenic mouse according to claim 1, wherein said uroplakin promoter is uroplakin II promoter.
- 3. The transgenic mouse according to claim 2, wherein said uroplakin II promoter is mouse uroplakin II promoter.
- 4. The transgenic mouse according to claim 3, wherein said oncogene operably linked to said mouse uroplakin II promoter is SV40 large T antigen.
- 5. The transgenic mouse according to claim 3, wherein said oncogene operably linked to said mouse uroplakin II promoter is H-ras.
- 6. The transgenic mouse according to claim 3, wherein said functionally inactivated tumor suppressor gene operably linked to said mouse uroplakin II promoter is p53.
- 7. The transgenic mouse according to claim 1, wherein said oncogene is selected from the group consisting of SV40 large T antigen, H-ras, Neu/erbB-2, and c-myc.
- 8. The transgenic mouse according to claim 1, wherein said functionally inactivated tumor suppressor gene is selected from the group consisting of functionally inactivated p53, p16, and retinoblastoma gene.
- 9. The transgenic mouse according to claim 1, wherein said uroplakin promoter is selected from the group consisting of uroplakin Ia, uroplakin Ib, uroplakin II and uroplakin III.
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application is a continuation-in-part of application Ser. No. 08/969,315, filed Nov. 13, 1997, which is a continuation-in-part of application Ser. No. 08/907,800, filed Aug. 8, 1997, now U.S. Pat. No. 6,001,646, which is a continuation-in-part of application Ser. No. 08/464,961, filed Jun. 5, 1995, now U.S. Pat. No. 5,824,543, the entire contents of all three prior applications are hereby incorporated by reference.
GOVERNMENT LICENSE RIGHTS
The U.S. Government has a paid up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as provided for by the terms of National Institutes of Health Grant Nos. DK39753 and DK49469 and a Veterans Administration Merit Review Grant.
Non-Patent Literature Citations (10)
Entry |
Hammer et al., Journal of Animal Science, vol. 63, pp. 269-278, 1986.* |
Ebert et al., Molecular Endocrinology, vol. 2, pp. 277-283, 1988.* |
Mullins et al., Journal of Clinical Investigations, vol. 998, No. 11, pp. S37-S40, 1996.* |
Wall, Theriogenology, vol. 45, pp. 57-68, 1996.* |
Kappel et al., Current Opinion in Biotechnology, vol. 3, pp. 548-553, 1992.* |
Strojek & Wagner, Genetic Engineering: Principles and Methods, vol. 10, pp. 221-246, 1988.* |
Database Medline on Dialog, US National Library of Medicine, No. 97137677 (1996). |
Database Medline on Dialog, US National Library of Medicine, No. 95148601 (1995). |
Database Medline on Dialog, US National Library of Medicine, No. 96373865 (1996). |
Database Medline on Dialog, US National Library of Medicine, No. 92297161 (1992). |
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
08/969315 |
Nov 1997 |
US |
Child |
09/083541 |
|
US |
Parent |
08/907800 |
Aug 1997 |
US |
Child |
08/969315 |
|
US |
Parent |
08/464961 |
Jun 1995 |
US |
Child |
08/907800 |
|
US |